Skip to main content
Log in

Computer-Aided Dosage Form Design. II. Methods for Defining a Zero-Order Sustained-Release Delivery System of Maximum Formulating Flexibility

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Classical methods employing pharmacokinetic data to calculate zero-order release rates for sustained release products require that a constant-rate drug delivery system must have a duration which is exactly equal to the desired dosage interval. This traditional approach fails to establish the minimum acceptable duration and also fails to provide any flexibility in the formulation goal. While it does calculate one pair of duration and dose values, there are infinite pairs of values capable of maintaining the desired plasma concentrations using the selected dosing interval. In the current method, computer simulations are used to establish the boundary conditions within which any pair of duration and dose values will maintain the desired levels when administered on the chosen dosing interval. By comparing the boundary conditions for every subject in a group, a single set of conditions which would work for the entire group can be selected. These final limits represent the broadest specifications for zero-order drug delivery system design for that particular drug combined with the plasma concentration goals and the desired dosing interval. The method is illustrated using theophylline pharmacokinetics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

REFERENCES

  1. P. G. Welling and M. R. Dobrinska. In J. R. Robinson (ed.), Sustained and Controlled Release Drug Delivery Systems, Marcel Dekker, New York, 1978, pp. 631–716.

    Google Scholar 

  2. E. Nelson. J. Am. Pharm. Assoc. Sci. Ed. 46:572–578 (1957).

    Google Scholar 

  3. M. Rowland and A. H. Beckett. J. Pharm. Pharmacol. 16 (Suppl.):156T (1964).

    Google Scholar 

  4. J. R. Robinson and S. P. Erikson. J. Pharm. Sci. 55:1254–1262 (1966).

    Google Scholar 

  5. M. G. Dobrinska and P. G. Welling. J. Pharm. Sci. 64:1728–1729 (1975).

    Google Scholar 

  6. K. C. Kwan. In J. R. Robinson (ed.), Sustained and Controlled Release Drug Delivery Systems, Marcel Dekker, New York, 1978, pp. 595–629.

    Google Scholar 

  7. J. D. Rogers and K. C. Kwan. In J. Urquhart (ed.), Controlled-Release Pharmaceuticals, American Pharmaceutical Associations, Washington, D.C., 1981, pp. 95–119.

    Google Scholar 

  8. R. G. Weigand and J. D. Tailor. Biochem. Pharmacol. 3:256–261 (1960).

    Google Scholar 

  9. E. Kruger-Theimer and S. P. Eriksen. J. Pharm. Sci. 55:1249–1254 (1966).

    Google Scholar 

  10. J. R. Robinson and S. P. Eriksen. J. Pharm. Sci. 59:1796–1800 (1970).

    Google Scholar 

  11. R. E. Notari. Biopharmaceutics and Clinical Pharmacokinetics, an Introduction, 4th ed., Marcel Dekker, New York, 1987, pp. 109, 191–208, 387–392.

    Google Scholar 

  12. J. G. Wagner. Fundamentals of Clinical Pharmacokinetics, Drug Intelligence, Hamilton, Ill., 1975, pp. 136–144.

    Google Scholar 

  13. T. Y. Lee and R. E. Notari. Pharm. Res. 4:311–316 (1987).

    Google Scholar 

  14. P. M. Loughnan, D. S. Sitar, R. I. Ogilvie, A. Eisen, Z. Fox, and A. H. Neims. J. Pediat. 5:874–879 (1976).

    Google Scholar 

  15. H. S. Kaumeier, O. H. Kehrhahn, G. Neugebauer, D. Schuppan, J. A. Schwarz, and A. H. Staib. Arzneim-Forsch. 34:92–95 (1984).

    Google Scholar 

  16. P. Bolme, M. Eriksson, G. Lonnerholm, and L. Paalzow. Acta Pharmacol. Toxicol. 51:401–406 (1982).

    Google Scholar 

  17. F. W. H. M. Merkus and L. Hendeles (eds.). Sustained Release Theophylline: A Biopharmaceutical Challenge of a Clinical Need, Exerpta Medica, Amsterdam, 1983.

    Google Scholar 

  18. P. G. Welling, L. L. Lyons, W. A. Craig, and G. A. Trachta. Clin. Pharmacol. Ther. 17:475–481 (1975).

    Google Scholar 

  19. D. L. Spangler, D. D. Kalof, F. L. Bloom, and H. J. Wittig. Ann. Allergy 40:6–13 (1978).

    Google Scholar 

  20. E. R. Barnhart. Physicians' Desk Reference, 40th ed., Medical Economics, Oradell, N.J., 1987, p. 1048.

    Google Scholar 

  21. G. S. Avery (ed.). Drug Treatment, Principles and Practice of Clinical Pharmacology and Therapeutics, Publishing Sciences Group, Acton, Mass., 1976, p. 571.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, TY., Notari, R.E. Computer-Aided Dosage Form Design. II. Methods for Defining a Zero-Order Sustained-Release Delivery System of Maximum Formulating Flexibility. Pharm Res 4, 385–391 (1987). https://doi.org/10.1023/A:1016478127409

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016478127409

Navigation